Norway · Delayed Price · Currency is NOK Medistim ASA Earnings Call Transcripts
Fiscal Year 2025
-
Record sales and profit in 2025, with strong growth in Americas and imaging products. U.S. tariffs offset by price increases, and a direct office opened in Japan to drive further expansion. Dividend of NOK 8 per share proposed.
-
Record Q3 and year-to-date results with strong revenue and profit growth, led by Americas and Asia-Pacific. Imaging and cardiac products showed robust performance, while EMEA lagged due to high market penetration. Outlook remains positive, with focus on U.S., China, and vascular segment expansion.
-
Second quarter and first half 2025 saw record sales and profit growth, led by strong performance in the Americas and Asia Pacific, improved gross margins, and a robust product mix. Outlook is positive with expected benefits from new software launches and price increases.
-
Q1 2025 saw record revenue and EBIT, with all regions and product lines contributing to strong growth. Gross margin and EPS improved significantly, and the launch of the INTUI platform is expected to drive further gains. Dividend and share buyback programs were executed.
Fiscal Year 2024
-
Record Q4 sales and strong full-year growth driven by Americas and EMEA offset APAC weakness. EBIT and profit after tax were stable, with improved gross margin and a proposed higher dividend. Launch of INTUI software and new clinical studies support a positive 2025 outlook.
-
Accelerated growth is expected through innovation, expanded direct market coverage, and the launch of the INTUI software platform, which modernizes surgical workflows and reporting. Clinical studies and new business models support broader adoption, while financial guidance targets NOK 1 billion in annual sales within a few years.
-
Q3 saw 7% sales growth in NOK, led by Americas' strong recovery, while EMEA and APAC declined for the quarter but EMEA remains up year-to-date. EBIT margin normalized at 24%, with higher costs from new direct operations and increased R&D spend. Vascular and flow products drove growth, while imaging sales lagged.
-
Record Q2 sales and a strong EBIT margin recovery highlight robust performance, with EMEA leading growth and third-party products supporting revenue. Direct market expansion and inventory normalization are expected to further improve margins and cash flow.